bioRxiv · 10.1101/2025.08.26.670480
Whole-organism screening in a zebrafish model of CLN2 disease identifies pregnenolone as a modulator of lysosomal functions with anti-epileptic properties
Abstract
Lysosomal storage disorders (LSDs), a group of inherited genetic diseases, are often associated with early-onset neurodegeneration and refractory epileptic seizures. In CLN2 disease, an LSD caused by recessively inherited dysfunction of lysosomal serine protease Tripeptidyl Peptidase 1 (TPP1), lysosomes are functionally impaired through a characteristic accumulation of subcellular materials. Here, we develop and apply a whole-organism screening workflow in tpp1-/- zebrafish to identify small molecules that suppress epileptic seizures - a hallmark of the human disease - in this model. Among 640 US Food and Drug Administration-approved drugs, pregnenolone, an endogenous precursor for steroid biosynthesis, efficiently suppresses seizures and cell death in tpp1-/- zebrafish. Using a semi-automated high-content workflow, we further show that pregnenolone normalizes lysosomal architecture in tpp1-/- zebrafish. Pregnenolone stimulates steroid hormone biosynthesis and related gene expression, which is dysregulated in tpp1-/- zebrafish. Taken together, tpp1-/- zebrafish are a suitable model to study CLN2 disease, in which we have identified pregnenolone as a candidate with therapeutic properties.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Kiani, L. N., Civiletto, G., Lizzo, G., Zdebik, A., Brickell, G., Mahmood, F., Nalkos, D. D., Michaelides, L., Eldridge, P., Young, E. M., McPherson, H., Campanella, M., Gut, P., Russell, C.. 2025-08-27. Whole-organism screening in a zebrafish model of CLN2 disease identifies pregnenolone as a modulator of lysosomal functions with anti-epileptic properties. https://doi.org/10.1101/2025.08.26.670480
Cite the original work for its findings. Save a collection to share your selection of sources.